Aura Biosciences (NASDAQ:AURA) Earns “Market Outperform” Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Aura Biosciences (NASDAQ:AURA) in a report released on Wednesday morning, Benzinga reports. JMP Securities currently has a $19.00 price objective on the stock.

Separately, HC Wainwright started coverage on shares of Aura Biosciences in a research report on Thursday, July 25th. They set a buy rating and a $21.00 price objective on the stock.

Aura Biosciences Price Performance

NASDAQ AURA opened at $7.95 on Wednesday. The firm’s fifty day moving average price is $8.25 and its 200 day moving average price is $7.89. The company has a market capitalization of $393.87 million, a price-to-earnings ratio of -4.27 and a beta of 0.40. Aura Biosciences has a 12 month low of $5.99 and a 12 month high of $12.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Matrix Capital Management Company LP grew its position in Aura Biosciences by 29.1% during the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after purchasing an additional 1,560,000 shares during the last quarter. Eventide Asset Management LLC boosted its holdings in shares of Aura Biosciences by 91.8% in the fourth quarter. Eventide Asset Management LLC now owns 5,802,682 shares of the company’s stock valued at $51,412,000 after acquiring an additional 2,777,777 shares in the last quarter. Long Focus Capital Management LLC boosted its holdings in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares in the last quarter. Regency Capital Management Inc. DE boosted its holdings in shares of Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after acquiring an additional 80,162 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Aura Biosciences in the fourth quarter valued at about $5,317,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.